Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use

Journal of Clinical Investigation

Volumn 97, Issue 3, 1996, Pages 865-869

  Kaveri, Srini ^a,e   Vassilev, Tchavdar ^a   Hurez, Vincent ^a   Lengagne, Renée ^b   Lefranc, Céline ^a   Cot, Sylvie ^c   Pouletty, Philippe ^d   Glotz, Denis ^a   Kazatchkine, Michel D ^a  

^a INSERM   (France)

^b INSTITUT COCHIN   (France)

^c Pharmacia Biosensor AB   (France)

^d GENZYME CORPORATION   (United States)

^e HÔPITAL BROUSSAIS   (France)

Author keywords

autoimmunity; HLA; immunopathology; immunotherapy; IVIg

Indexed keywords

CD8 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B7 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; PROTEIN ANTIBODY;

AFFINITY CHROMATOGRAPHY; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOMODULATION; INFLUENZA VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030019996     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118488     Document Type: Article

References (36)

1. Dwyer, J.M. 1992 Manipulating the immune system with immune globulin. N Engl J. Med. 326:107-116.
2. Glowacki, L.S., and F.M. Smaill. 1994. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients, a metaanalysis. Clin Transplant. 8:10-18
3. Bass, E.B., N.R Powe, S.N. Goodman, S.L. Graziano, R.I. Griffiths, T S Kickcler, and J.R. Wingard. 1993. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant. 12:273-282.
4. Sullivan, K.M., K.G. Kopecky, J. Jocom, L. Fischer, C.D. Buckner, J.D. Meyers, J.W. Counts, R.A. Bowden, F.B. Petersen, R.P. Witherspoon, et al. 1990. Immunomodulatory and anti-microbial efficacy of intravenous immunoglobulin in bone marrow transplantation. N. Engl. J. Med. 323:705-709.
5. Kazatchkine, M.D., G. Dietrich, V Hurez, N. Ronda, B. Bellon, F. Rossi, and S.V. Kaveri. 1994. V Region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol. Rev. 139.79-107.
6. Sultan, Y., M.D. Kazatchkine, P. Maisonneuve, and U.E. Nydegger 1984. Anti-idiotypic suppression of autoantibodies to Factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobuhn. Lancet ii:765-768.
7. Rossi, F., and M.D. Kazatchkine. 1989. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J. Immunol. 143:4104-4109.
8. Dietrich, G., and M.D. Kazatchkine 1990 Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies J. Clin. Invest 85:620-625.
9. Marchalonis, J J., H. Kaymaz, F Dedeoglu, S.F. Schlutter, D.E. Yocum, and A.B. Edmundson. 1992. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proc. Natl Acad. Sci. USA. 89:3325-3329.
10. Schifferli, J.A., J.H. Saurat, and L. Didierjean. 1991. Immunomodulatory effects of intravenous immunoglobulin G. J. Rheumatol 18:937-939
11. Vassilev, T., C Gelin, S.V. Kaveri, M.T. Zilber, L Boumsell, and M.D. Kazatchkine 1993. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg) Clin. Exp Immunol. 92:369-372.
12. Hurez, V., S.V. Kaveri, A. Mouhoub, G. Dietrich, J.C. Mani, D Klatzmann, and M.D. Kazatchkine. 1994. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (Intravenous immunoglobulin, IVIg). Ther. Immunol 1:269-278.
13. Bjorkman, P.J., M.A. Saper, B. Samraoui, W.S. Bennet, J.L. Strominger, and D C. Wiley. 1987. Structure of the human class I histocompatibility antigens Nature (Lond) 329 506-511.
14. Clayberger, C., S.C. Lyu, P. Pouletty, and A.M. Krensky 1993 Peptides corresponding to T-cell receptor-HLA contact regions inhibit class I-restricted immune responses. Transplant Proc 25:477-478
15. Nisco, S., P. Vriens, G. Hoyt, S. Lyu, F. Farfan, P. Pouletty, A.M. Krensky, and C. Clayberger. 1994 Induction of allograft tolerance in rats by an HLA class-I-derived peptide and cyclosporine A. J. Immunol. 152:3786-3792
16. Bourgault, I., A. Gomez, E. Gomard, F. Picard, and J.P. Lévy. 1989. A virus-specific CD4+ cell-mediated cytolytic activity revealed by CD8+ cell elimination regularly develops in uncloned human anti-viral cell lines. J Immunol 142:252-256.
17. Zemmour, J., and P. Parham. 1992. HLA class I nucleotide sequences. Immunugenetics. 37:239-243.
18. Buelow, R., W J. Burlingham, and C. Clayberger. 1995. Immunomodulation by soluble HLA class I. Transplantation. 59:649-654.
19. Glotz, D , J.P. Haymann, P. Niaudet, P. Lang, P. Druet, and J. Bariety. 1995. Successful kidney transplantation of immunized patients after desimmunization with normal human polyclonal immunoglobulins for intravenous use (IVIg). Transplant Proc 27:1038-1039.
20. Glotz, D., J.-P. Haymann, N. Sansonetti, A. François, V. Menoyo-Calonge, J. Bariety, and P. Druet. 1993. Suppression of allo-anti HLA antibodies by high dose intravenous immunoglobulins (IVIg): a potential tool for transplantation of immunized patients. Transplantation 56:335-337.
21. Van Schaik, I.N., I. Lundkvist, M. Vermeulen, and A. Brand. 1992. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J. Clin. Immunol. 12:325-334.
22. Delfraissy, J F , G Tcherma, Y. Laurian, C. Wallon, and P Galanaud. 1985. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br. J. Haematol. 60:315-322
23. Amran, A., H. Renz, G. Lack, K. Bradley, and E.W. Gelfand. 1994. Suppression of cytokine-dependant human T-cell proliferation by intravenous immunoglobulin. Clin. Immunol. Immunopathol. 73:180-186.
24. Takei, S., Y Arora, and S.M. Walker. 1993. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J. Clin. Invest. 91:602-607.
25. Blasczyk, R., U. Westhoff, and H. Grossewilde. 1993. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet. 341:789-790.
26. Avrameas, S., B. Guilbert, and G. Dighiero. 1981. Natural antibodies against tubulin, actin, myoglobin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera and monoclonal immunoglobulins from multiple myeloma and Waldenström's macroglobulinemia may express similar antibody specificities. Ann. Inst. Pasteur Immunol 132C:231-236
27. Guilbert, B., G. Dighiero, and S. Avrameas. 1982 Naturally occurring antibodies against nine common antigens in normal human sera. I. Detection, isolation, and characterization. J. Immunol. 128:2779-2787
28. Yadin, O., B. Sarov, L. Naggan, H. Slor, and Y. Shoenfeld. 1989. Natural autoantibodies in the serum of healthy women: a five year follow-up. Clin. Exp Immunol 75:402-406
29. Hurez, V., S V. Kaveri, and M.D. Kazatchkine. 1993. Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur. J. Immunol. 23:783-789.
30. Berneman, A., B. Guilbert, S. Eschrich, and S. Avrameas. 1993. IgG auto- and polyreactivities of normal human sera. Mol. Immunol. 30:1499-1510.
31. Lam, L., C.F. Whitsett, J.M. McNicholl, T.W. Hodge, and J. Hooper 1993. Immunologically active proteins in intravenous immunoglobulin. Lancet. 342:678
32. Gaur, A., and C.G. Fathman 1994. Immunotherapeutic strategies directed at the trimolecular complex. Adv. Immunol 56:219-265.
33. Steinman, L. 1991 The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease. Adv. Immunol 49: 357-379.
34. Waldman, H. 1989. Manipulation of T cell responses with monoclonal antibodies Ann. Rev. Immunol. 7:407-444.
35. Wofsy, D., and W.E Seaman. 1985. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J. Exp. Med 161:378-391.
36. Wacholtz, M.C., and P.E Lipsky. 1992. Treatment of lupus nephritis with CD5 PLUS, an immunoconjugate of an anti-CD5 monoclonal antibody and ricin A chain. Arthrits & Rheum. 35:837-839.